727416-64-0

Usage

Also known as

Sunitinib
A common name for the compound 1H-Indole, 3-(1-methylethyl)-1-[(4-methylphenyl)sulfonyl]-.
3. Potent inhibitor of receptor tyrosine kinases
Sunitinib effectively inhibits the activity of receptor tyrosine kinases, which are proteins involved in cell signaling pathways.
4. Involved in the growth and spread of cancer cells
By inhibiting receptor tyrosine kinases, Sunitinib helps to prevent the growth and spread of cancer cells.
5. Approved for the treatment of advanced renal cell carcinoma
Sunitinib has been approved as a treatment option for patients with advanced-stage kidney cancer.
6. Approved for the treatment of imatinib-resistant gastrointestinal stromal tumors
Sunitinib is effective in treating gastrointestinal stromal tumors that do not respond to imatinib, a different cancer treatment drug.
7. Blocks signals that promote cancer cell growth and angiogenesis
Sunitinib works by inhibiting the signals that stimulate the growth of cancer cells and the formation of new blood vessels to supply tumors.
8. Oral medication
Sunitinib is available in the form of an oral medication, making it convenient for patients to take.
9. Demonstrated significant benefits in the treatment of various types of cancer
Clinical studies and real-world use have shown that Sunitinib provides meaningful benefits in the treatment of different cancer types.

Upstream product

• 16886-00-3 3-isopropyl indole 
• 98-59-9 p-toluenesulfonyl chloride 
• 859164-50-4 2-[1-(toluene-4-sulfonyl)-1H-indol-3-yl]-propan-2-ol 

Downstream Products

• 16886-00-3 3-isopropyl indole 

Relevant academic research and scientific papers

Catalytic asymmetric hydrogenation of indoles using a rhodium complex with a chiral bisphosphine ligand PhTRAP

Highly enantioselective hydrogenation of N-protected indoles was successfully developed by use of the rhodium catalyst generated in situ from [Rh(nbd)2]SbF6 and the chiral bisphosphine PhTRAP, which can form a trans-chelate complex with a transition metal atom. The PhTRAP-rhodium catalyst required a base (e.g., Cs2CO3) for the achievement of high enantioselectivity. Various 2-substituted N-acetylindoles were converted into the corresponding chiral indolines with up to 95% ee. The hydrogenations of 3-substituted N-tosylindoles yielded indolines possessing a stereogenic center at the 3-position with high enantiomeric excesses (up to 98% ee).

CB1 MODULATOR COMPOUNDS

Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention are useful as in the treatment, prevention and suppression of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders (e.g., multiple sclerosis, Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis), cerebral vascular accidents, head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, particularly to opiates, alcohol, and nicotine. The compounds are also useful for the treatment of obesity or eating disorders associated with excessive food intake and complications associated therewith.